Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

07. Juli 2026 05:00 ET | Quelle: ITM Isotope Technologies Munich SE

ITM Announces Primary Results from the Phase 3 COMPETE Trial Published in The Lancet Comparing ¹⁷⁷Lu-edotreotide (ITM-11) vs. Everolimus in Advanced GEP-NETs

Investigational n.c.a. 177Lu-edotreotide (ITM-11) demonstrated a significantly higher progression-free survival and objective response rate vs. everolimus Garching / Munich, July 7, 2026 – ITM...
18. Oktober 2025 05:15 ET | Quelle: ITM Isotope Technologies Munich SE

ITM Announces Phase 3 COMPETE Data Demonstrating a Statistically Significant Higher Objective Response Rate with n.c.a. 177Lu-edotreotide (ITM-11) vs. Everolimus in Patients with Gastroenteropancreatic Neuroendocrine Tumors at ESMO 2025

Study data also showed prolonged progression-free survival with 177Lu-edotreotide compared to everolimus across patient subgroups Berlin, Germany, October 18, 2025 – ITM Isotope Technologies Munich...
13. März 2025 06:30 ET | Quelle: ITM Isotope Technologies Munich SE

ITM Announces Updates to Commercial Leadership

Dr. Sebastian Marx, ITM’s chief business officer and member of the Executive Board, is stepping down effective July 20, 2025 after nearly two decades at the company Roger Estafanos, currently U.S....
25. Februar 2025 05:00 ET | Quelle: ITM Isotope Technologies Munich SE

ITM to Present Top Line Results from Phase 3 COMPETE Trial with [177Lu]Lu-edotreotide for the Treatment of Grade 1 & Grade 2 Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) at European Neuroendocrine Tumor Society (ENETS) Conference

Garching / Munich, February 25 2025 – ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, today announced that it will provide topline data results from its Phase...